TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Merck Vaccine Not Linked to Infant Malady A Merck vaccine designed to protect infants against rotavirus doesn't appear to be associated with an increased risk of a potentially life-threatening intestinal problem, health officials said. feeds.wsjonline.com |
Philips Buys Respironics for $5 Billion Philips said it would acquire U.S.-based health-care firm Respironics for $5.1 billion in cash, the latest in a string of U.S. acquisitions in that sector. feeds.wsjonline.com |
WakeMed works to partner with doctors at Brier Creek center RALEIGH - WakeMed Health & Hospitals wants to build a surgery center in Brier Creek that would operate as a joint venture with physicians - a first for the nonprofit hospital. feeds.bizjournals.com |
Genzyme's Revenue Surges Genzyme's quarterly net fell 8.2% on an investment-related charge, but the biotechnology company's revenue jumped on strong demand for its treatments for Gaucher and renal diseases. feeds.wsjonline.com |
Apotex Sues FDA to Recover Its 180-Day Exclusivity on Generic Plavix Aaron F. Barkoff submits: In November 2001, Apotex became the first company to file an ANDA for a generic version of Plavix (clopidogrel bisulfate) with a paragraph IV certification. In March 2002, Sanofi-Synthelabo and Bristol-Myers Squibb (BMY) sued Apotex for infringing the Orange Book-listed patent, U.S. Patent No. 4,847,265, thereby initiating an automatic 30-month stay of FDA approval of Apotex's ANDA.With the patent litigation still pending, the stay expired in May 2005. In January 2006, FDA granted final approval to Apotex's ANDA. The litigation was proceeding toward trial when, on August 8, 2006, Apotex launched its generic clopidogrel bisulfate product at risk, starting its 180-day exclusivity period. 23 days later, the U.S. District Court for the Southern District of New York preliminarily enjoined (pdf file) Apotex from continuing to sell its generic version of Plavix. Thus, Apotex was enjoined, but its exclusivity continued to run.Complete Story » seekingalpha.com |